Phase 2 Schizophrenia Trial, Recruiting NCT07288333 Sponsor: Neurocrine Biosciences Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT07288333
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 18 and 55 years old
  • People who have been diagnosed with schizophrenia for at least 1 year before the screening visit
  • People who are currently experiencing a worsening or return of schizophrenia symptoms that started less than 2 months before screening and who are currently in hospital because of this
  • People who have previously responded well to at least one antipsychotic medication (other than clozapine) during a past episode

Who may not be able to join:

  • People who are considered to be at immediate risk of harming themselves or others
  • People who have a history of epilepsy, seizures, or convulsions
  • People who have low blood pressure when standing up, or a history of certain heart or blood vessel conditions, including high blood pressure in the lungs, blocked arteries in the heart, thickened heart muscle, heart attack, heart failure, or moderate to severe heart valve problems, among other heart-related conditions (confirm with trial site)
  • People who are currently taking certain medications that are not allowed in this trial (confirm with trial site for the specific list)
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Development Lead, Neurocrine Biosciences

Phone: 1-877-641-3461

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Neurocrine Biosciences
Registry
ClinicalTrials.gov
Start date
16 February 2026
Est. completion
1 August 2027

Where this trial is recruiting

🇧🇬 Bulgaria 🇬🇧 United Kingdom

Primary endpoints

Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov